Skip to main content

Dr. Bar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Bar's full profile

Already have an account?

  • Office

    3400 Spruce Street
    8 Penn Tower
    Philadelphia, PA 19104
    Phone+1 215-662-6932
    Fax+1 205-934-5155

Education & Training

  • University of Alabama Medical Center
    University of Alabama Medical CenterFellowship, Infectious Disease, 2006 - 2009
  • Virginia Commonwealth University Health System
    Virginia Commonwealth University Health SystemResidency, Internal Medicine, 2002 - 2005
  • University of Iowa Roy J. and Lucille A. Carver College of Medicine
    University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 2002

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 2011 - 2024
  • AL State Medical License
    AL State Medical License 2006 - 2011
  • VA State Medical License
    VA State Medical License 2002 - 2006
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Infectious Disease

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • HIV-1 Latent Reservoir Size and Diversity Are Stable Following Brief Treatment Interruption  
    Robert F. Siliciano, Jonathan Z. Li, Katharine J. Bar, James Hoxie, Pablo Tebas, The Journal of Clinical Investigation

Press Mentions

  • FDA Approves COVID Antibody Treatment for Immunocompromised
    FDA Approves COVID Antibody Treatment for ImmunocompromisedAugust 3rd, 2021
  • Regeneron’s Antibody Drug Can Help Prevent COVID-19 from Spreading Among Household Members
    Regeneron’s Antibody Drug Can Help Prevent COVID-19 from Spreading Among Household MembersApril 12th, 2021
  • FDA’s Emergency Authorization for Convalescent Plasma in Covid-19 Sparks Controversy
    FDA’s Emergency Authorization for Convalescent Plasma in Covid-19 Sparks ControversyAugust 24th, 2020
  • Join now to see all

Professional Memberships